Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Gastrointestinal Cancers
•
Anal Cancer
What would you include in your radiation field for a cT2N1 perianal squamous cell carcinoma in the setting of VIN3, CIN3 and AIN3?
Related Questions
Would you offer inguinal nodal RT to a patient with anal SCC (pT1N1a, + inguinal node) following APR in the setting of prior prostate + pelvic nodal radiation?
In patients with T1 anal squamous cell cancer status post local excision with a close margin, would you recommend close observation or adjuvant concurrent chemoradiation?
Given the results of PLATO anal cancer study, is 4140 cGy the new standard for early stage anal cancer?
In a patient with a mid-esophageal squamous cell carcinoma with tracheal invasion confirmed on bronchoscopy, would you treat with definitive chemo-radiation with curative intent?
Which GI cancer patients do you use oral contrast in staging CT scans?
How would you manage a borderline resectable pancreatic cancer s/p induction chemo + chemo-RT who was unable to go to surgery?
Would you consider long course pelvic CRT after neoadjuvant chemotherapy in a patient with low lying, locally advanced rectal adenocarcinoma when you're unable to meet small bowel constraints?
In a patient with pancreatic cancer who is heterozygous for the ATM c.875C>T (Pro292Leu) mutation with functional impairment in the gene product, is there any data or recommendation to support using SBRT vs. chemo-RT?
Do you use different dose constraints for large bowel vs. small bowel?
What is the best way to proceed in anal cancer surveillance if PET avidity of the primary is reduced, but still avid at time point <6 months s/p chemo-RT?
